Abstract:Background and purpose:Intensity-modulated radiation therapy(IMRT) enables the delivery of higher radiation dose to the primary disease and neck metastases while sparing the organs/tissues at risk(OARs) thereby IMRT combined with chemotherapy enhancing the therapeutic ratio.How to further improve the efficacy became a common topic of the oncologists.Different stages of nasopharyngeal carcinoma(NPC) have different efficacy.The subgroups in the same stage whether have different efficacy still remain to be studied.This study retrospectively analyzed the outcome of clinical stage Ⅲ NPC patients treated with IMRT after induction chemotherapy with or without adjuvant chemotherapy.Methods:From Nov.2003 to Jun.2006,133 patients with untreated stage Ⅲ NPC were analyzed retrospectively.According to the AJCC 2002 staging system: 7(5.3%) patients were T3N0,39(29.3%) patients were T3N1,48(36.1%) patients were T2N2,39(29.3%) patients were T3N2.All the patients received IMRT.One hundred and twenty-four patients received induction chemotherapy.Twenty-four patients received concurrent chemotherapy.Thirty-three patients received adjuvant chemotherapy.Results:The 5-year local-regional free survival(LRFS),distant metastasis-free survival(DMFS),disease-free survival(DFS) and overall survival(OS) were 90.9%,89.9%,82.5%,and 83.4%.The 5-year LRFS,DMFS,DFS and OS of patients with T2,T3 disease were 93.1% vs 89.4%(χ2=0.407,P=0.524),91.2% vs 89.3%(χ2=0.152,P=0.697),86.5% vs 80.0%(χ2=0.899,P=0.343),81.1% vs 84.7%(χ2=0.311,P=0.577).The 5-year LRFS,DMFS,DFS and OS of patients with N0-1,N2 disease were 91.1% vs 90.9%(χ2=0.007,P=0.933),97.8% vs 85.8%(χ2=4.69,P=0.030),88.9% vs 79.2%(χ2=1.746,P=0.1836),93.5% vs 78.1%(χ2=5.052,P=0.025).Adjuvant chemotherapy provided no significant benefit to IMRT in stage Ⅲ NPC,but was responsible for higher rates of grade 3 or 4 toxicities(48% vs 27.6%,P<0.005).Conclusion:IMRT combined with chemotherapy is an effective treatment for patients diagnosed with stage Ⅲ NPC.Patients with N0-1 disease have a better OS and DMFS than patients with N2 disease.Further improving the effect of stage Ⅲ NPC still need to explore the significance of adjuvant chemotherapy and look for more effective chemotherapy drugs,targeted drugs and more reasonable combined treatments.

Comparison of efficacy and safety between intensity-modulated radiotherapy combined with chemotherapy plus targeted therapy and intensity-modulated radiotherapy combined with chemotherapy for locally advanced nasopharyngeal carcinoma

Comparison of long-term efficacy between intensity-modulated radiotherapy with concurrent chemotherapy and neoadjuvant chemotherapy followed by intensity-modulated radiotherapy with concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma

Comparison of long-term efficacy between concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

An Analysis of Efficacy of Intensity-Modulated Radiotherapy with Concurrent Chemotherapy for Stage T1-2 N1 Nasopharyngeal Carcinoma

Comparison of long-term efficacy between intensity-modulated radiotherapy with concurrent chemotherapy and neoadjuvant chemotherapy followed by intensity-modulated radiotherapy with concurrent chemotherapy in patients with locally advanced nasopharyngeal

IMRT Combined with Concurrent Chemotherapy Plus Adjuvant Chemotherapy Versus IMRT Combined with Concurrent Chemotherapy Alone in Patients with Nasopharyngeal Carcinoma

Comparison of efficacy of induction chemotherapy plus intensi-ty-modulated radiotherapy and concurrent chemo-radiotherapy plus adjuvant chemotherapy for patients with loco-regionally ad-vanced nasopharyngeal carcinoma

Clinical study of docetaxel plus nedaplatin combined with concurrent intensity-modulated radiotherapy for locally-advanced nasopharyngeal carcinoma

Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era

Comparison of long-term efficacy between concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for stage Ⅱ nasopharyngeal carcinoma

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma

Omission of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiation Therapy: A Paired Cohort Study

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma

Efficacy of clinical stage Ⅲ nasopharyngeal carcinoma treated by intensity-modulated radiation therapy combined with chemotherapy

[Concurrent Control Study of Different Radiotherapy for Primary Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy].

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Role of intensity-modulated radiation therapy combined with chemotherapy in patients with stage T 1-2N 1M 0 nasopharyngeal carcinoma: a retrospective study

Long-term results of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone

Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy Versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Retrospective Analysis